Philadelphia/ Science, Tech & Medicine

Plymouth Meeting Biotech Inovio Wins First-Ever FDA Nod After 43-Year Wait

AI Assisted Icon
Published on November 18, 2026
Plymouth Meeting Biotech Inovio Wins First-Ever FDA Nod After 43-Year Wait660 W. Germantown Pike, Suite 110 — Inovio Pharmaceuticals Base
Google Street View

A Plymouth Meeting biotech company that spent 43 years without a single approved drug finally has one. The Food and Drug Administration cleared Inovio's injectable DNA immunotherapy Voceryq for adults with recurrent respiratory papillomatosis, a rare disease that causes recurring, usually noncancerous growths in the respiratory tract, including around the vocal cords, and can affect patients' voice and breathing. The condition is caused primarily by human papillomavirus and often forces patients into repeated surgeries just to remove the growths and keep their airway open.

The FDA decided on Inovio's application late Friday afternoon, according to a report from The Business Journals. Investors reacted almost instantly: Inovio's stock, which trades under the Nasdaq ticker INO, rose 230% in after-hours trading, climbing from 60 cents to $2 per share by 6:45 p.m. that evening, per the same report. The approval marks the first marketing clearance the FDA has ever issued for a DNA-based immunotherapy, a technology that uses DNA to instruct the body to produce proteins that help the immune system recognize and respond to disease.

Voceryq, known during development as INO-3107, is composed of two DNA plasmids — one encoding proteins specific to the HPV6 and HPV11 viruses behind the disease, and the other encoding human IL-12 to boost the immune response, according to Fierce Pharma. MedCity News reports that the therapy is given as one dose every three weeks for a total of four doses, and that it is the first plasmid DNA-based immunotherapy ever approved by the agency.

A Milestone Inovio Waited Decades For

Inovio CEO Jacqueline Shea said the approval validates the company's technology and called it a milestone, according to the Business Journals report. That sentiment reflects just how long the wait has been: the company had operated for 43 years without a single FDA-approved product before Voceryq's clearance. John George, a senior reporter at the Philadelphia Business Journal, authored the original Business Journals account that first detailed the approval and the stock swing that followed.

The clinical data behind the approval came from a Phase 1/2 trial that MedCity News' report describes as showing a statistically significant reduction in surgical interventions compared to the prior year. Among 26 participants who had undergone at least three surgeries in the previous year, seven showed a complete response, meaning they required no surgery during the 12 months of follow-up after treatment, per the outlet's reporting. Because the approval relied on that early-stage data, Inovio must now conduct a confirmatory study to verify the therapy's clinical benefit. Fierce Pharma reports that the study should enroll at least 50 adult and pediatric patients with the disease who required three or more surgeries in the 12 months before treatment with Voceryq.

A Six-Figure Price Tag, With Availability Still Weeks Away

Inovio set a list price of $115,000 per dose for Voceryq, or $460,000 for the complete four-dose series, the MedCity News report states. The company expects the drug to become available within the next 60 days of that report. Inovio, which is based in Plymouth Meeting, estimates that at least 25,000 people in the U.S. are living with the disease, based on its analysis of claims data — though MedCity News' separate account of the same estimate describes it instead as a roughly 25,000-adult market, and the dossier does not clarify whether the two figures describe the same population.

Not the First Drug to Market

Voceryq is not the first approved treatment for the disease. The FDA approved Precigen's injectable drug PAPZIMEOS in August 2025 as the first therapy for adults with recurrent respiratory papillomatosis, making Voceryq just the second drug approval in this rare indication, according to MedCity News. Precigen, based in Maryland and trading under the Nasdaq ticker PGEN, competes directly with Inovio in this market. The Business Journals reported that Precigen had generated $78.1 million in PAPZIMEOS sales since its launch the previous year, while Precigen's own third-quarter 2026 results, announced through PR Newswire, put PAPZIMEOS net revenue at $72.9 million for the quarter alone, up 37% sequentially, with launch-to-date net product revenue reaching $151 million. The PR Newswire release also says more than 500 patients had begun PAPZIMEOS treatment and more than 300 had completed it as of that announcement.

In its pivotal study, PAPZIMEOS showed a 51% complete response rate — 18 of 35 patients with no surgeries during the 12 months following treatment completion, per the same PR Newswire release. Shea, Inovio's CEO, has pointed to one difference between the two drugs: according to the MedCity News report, Voceryq does not require surgeries prior to its third or fourth doses, unlike what PAPZIMEOS's label calls for. Separately, a 2026 article in The Laryngoscope, published by Wiley Online Library, describes the disease as carrying clinical, financial and psychosocial burdens and notes that greater public awareness of airway HPV infection is needed, since the condition is preventable through HPV vaccination.